A nurse is giving discharge instructions to a patient who has been ordered Guaifenesin (Mucinex) to take BID for 3 days after discharge. What response by the patient lets her know that he understands how to take his medication?

The nurse should make the following responses regarding how albuterol helps the client's breathing:

• The medication will open the airways.
• The medication will prevent wheezing.

Albuterol is a bronchodilator medication commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing the smooth muscles in the airways, leading to the dilation of the bronchial tubes and increased airflow. This mechanism helps open up the airways and prevent or relieve symptoms such as wheezing, shortness of breath, and chest tightness.

The other options are incorrect because:

The medication will decrease coughing episodes: While albuterol may indirectly reduce coughing episodes by opening up the airways and improving airflow, its primary effect is on bronchodilation rather than directly targeting coughing.

The medication will stimulate the flow of mucus: Albuterol is not known to stimulate mucus flow. Instead, it focuses on bronchodilation to improve airflow in the lungs.

The medication will reduce inflammation: Albuterol is primarily a bronchodilator and does not have a significant anti-inflammatory effect. Other medications, such as corticosteroids, are typically used to address inflammation in respiratory conditions.

Leukotriene receptor antagonists (LTRAs) like Montelukast are commonly used in the treatment of asthma. They work by blocking the action of leukotrienes, which are inflammatory substances that can cause narrowing and inflammation of the airways in individuals with asthma. By preventing this inflammation, LTRAs help to reduce asthma symptoms and prevent asthma attacks.

The other options mentioned in the statements are not accurate or appropriate for teaching about Montelukast. Taking the medication only when experiencing symptoms is not the recommended approach, as LTRAs are typically taken regularly as part of ongoing asthma management. The statement about the therapeutic effect taking several weeks to notice is not accurate, as Montelukast can start to provide symptom relief within a shorter timeframe.

Additionally, the statement about increasing fiber and fluid intake to prevent constipation is unrelated to the use of Montelukast and may not apply to this medication specifically.